1-6 of 6
Rebecca Valentin, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Charles Herbaux, MD MSc, Christoph Kornauth, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Mary C Collins, BA, Rebecca Valentin, MD, Stephen Jun Fei Chong, PhD, Jehan Dupuis, MD, Adrien Daniel, Micha Srour, MD, Cecile Tomowiak, MD, Kamel Laribi, MD, Damien Roos-Weil, Cedric Rossi, MD PhD, Nicolas Vanlangendonck, MSc, Cecile Leyronnas, Fatiha Merabet, MD, Jean Valère Malfuson, MD, Mourad Tiab, Samuel Ng, MD PhD, Franck Morschhauser, MD, Philipp Bernhard Staber, MD PhD, Matthew S. Davids, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 807.
https://doi.org/10.1182/blood-2019-126773
Published: 2019
Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4281.
https://doi.org/10.1182/blood-2019-127293
Published: 2019
Journal Articles

Dynamic BH3 Profiling Predicts Patient Response and MRD Status in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Frontline Treatment with Kinase Inhibitor Plus FCR (KI+FCR)

Timothy Z. Lehmberg, BA, Rebecca Valentin, MD, Stacey M. Fernandes, BS, Jennifer R. Brown, MD PhD, Matthew S Davids
Journal: Blood
Blood (2018) 132 (Supplement 1): 4395.
https://doi.org/10.1182/blood-2018-99-115151
Published: 2018
Journal Articles

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Rebecca Valentin, MD, Marisa O. Peluso, MS, Timothy Z. Lehmberg, BA, Ammar Adam, DVM, Li Zhang, MA, Caroline M. Armet, BS, Jennifer L. Guerriero, PhD, Benjamin H. Lee, MD PhD, Vito J. Palombella, PhD, Pamela M. Holland, PhD, Alison M. Paterson, PhD, Matthew S. Davids, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4393.
https://doi.org/10.1182/blood-2018-99-110181
Published: 2018
Journal Articles

Dynamic BH3 Profiling to Assess the Effects of Novel Agents on Anti-Apoptotic Protein Dependence of CLL Cells

Rebecca Valentin, MD, Jing Deng, PhD, Elisa Ten Hacken, PhD, Timothy Z. Lehmberg, BA, Silvia Buonamici, PhD, Donna S. Neuberg, ScD, Catherine J. Wu, MD, Anthony Letai, MD PhD, Matthew S. Davids, MD MMSc
Journal: Blood
Blood (2017) 130 (Supplement 1): 4289.
https://doi.org/10.1182/blood.V130.Suppl_1.4289.4289
Published: 2017
Journal Articles

Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment

Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Jing Sun, PhD, Jing Deng, PhD, Angela Brooks, PhD, Lillian Werner, MS, Fara Faye Regis, BS, Michaela Gruber, MD PhD, Jessica Wong, BS, Zachary Cartun, BS, Michael Seiler, PhD, Peter Smith, PhD, Michael Thomas, PhD, Silvia Buonamici, PhD, Emanuela M. Ghia, PhD, Ekaterina Kim, PhD, Laura Z. Rassenti, PhD, Jan A. Burger, MD PhD, Thomas J. Kipps, MD, Matthew Meyerson, MDPhD, Donna S. Neuberg, ScD, Ruben D. Carrasco, MD PhD, Lili Wang, MD PhD, Matthew S. Davids, MD, Anthony Letai, MD PhD, Catherine J. Wu, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 264.
https://doi.org/10.1182/blood.V130.Suppl_1.264.264
Published: 2017